CRISPR/Cas9-mediated TGFβRII Disruption Enhances Anti-tumor Efficacy of Human Chimeric Antigen Receptor T Cells in Vitro

doi:10.21203/rs.3.rs-823875/v1

Download PDF

Research Article

CRISPR/Cas9-mediated TGFβRII Disruption Enhances Anti-tumor Efficacy of Human Chimeric Antigen Receptor T Cells in Vitro

https://doi.org/10.21203/rs.3.rs-823875/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 27 Nov, 2021

Read the published version in Journal of Translational Medicine →

You are reading this latest preprint version

Background: CAR T-cell therapy has been recently unveiled as one of the most promising cancer therapies in hematological malignancies. However, solid tumors mount a profound line of defense to escape immunosurveillance by CAR T-cells. Among them, cytokines with an inhibitory impact on the immune system such as IL-10 and TGFβ are of great importance: TGFβ is a pleiotropic cytokine, which potently suppresses the immune system and is secreted by a couple of TME resident and tumor cells.

Methods: In this study, we hypothesized that knocking out the TGFβ receptor II gene, could improve CAR T-cell functions in vitro and in vivo. Hereby, we used the CRISPR/Cas9 system, to knockout the TGFβRII gene in T-cells and could monitor the efficient gene knock out by genome analysis techniques. Next, Mesothelin or Claudin 6 specific CAR constructs were overexpressed via IVT-RNA electroporation or retroviral transduction and the poly-functionality of these TGFβRII KO CAR T-cells in terms of proliferation, cytokine secretion and cytotoxicity were assessed and compared with parental CAR T-cells.

Results: Our experiments demonstrated that TGFβRII KO CAR T-cells fully retained their capabilities in killing tumor antigen positive target cells and more intriguingly, could resist the anti-proliferative effect of exogenous TGFβ in vitro outperforming wild type CAR T-cells. Noteworthy, no antigen or growth factor-independent proliferation of these TGFβRII KO CAR T-cells has been recorded. TGFβRII KO CAR T-cells also resisted the suppressive effect of induced regulatory T-cells in vitro to a larger extent. Repetitive antigen stimulation demonstrated that these TGFβRII KO CAR T-cells will experience less activation induced exhaustion in comparison to the WT counterpart.

Conclusion: The TGFβRII KO approach may become an indispensable tool in immunotherapy of solid tumors, as it may surmount one of the key negative regulatory signaling pathways in T-cells.

Translational Medicine

CAR T-cell therapy

Coinhibitory T-cell signaling

TGFβ Receptor II

genome editing

CRISPR/Cas9 knockout

IVT-RNA

Adoptive cell transfer of antigen receptor modified T-cells is a promising new tool for the treatment of cancer. Besides the modification of T-cells with tumor specific T-cell receptors (TCRs), chimeric antigen receptor (CAR)-based therapies have come into focus for the treatment of several different tumor entities. CAR T-cell therapy can be regarded as one of the most promising cancer therapies in refractory hematological malignancies. The innovative idea of combining efficient, sensitive and HLA-independent antigen recognition properties of monoclonal antibodies and killing mechanism of T-cells made this system extraordinary in tracing and eradicating tumor cells [1], which has been clinically approved in patients with ‘liquid’ tumors such as B cell malignancies[2, 3]. However, solid tumors have a multi-faceted line of strategies to escape killing by CAR T-cells, these include but are not restricted to lack of tumor specific antigens on tumor cells, imposing hurdles in trafficking and penetration of T-cells into encapsulated tumors, which on top are characterized by a hostile, immunosuppressive tumor microenvironment (TME) along with intrinsic counter-regulatory mechanisms of T-cells [4].

TGFβ is one of the most critical regulators in the TME, and known to be secreted by many cancer cells such as ovarian cancer cells or by components of the immune system and stromal cells [5]. This cytokine is a pleiotropic cytokine which can modulate processes such as cell invasion, immune regulation governing suppression of host immune surveillance and regulatory T-cell differentiation, and microenvironment modification, altogether leading to tumor progression [6, 7]. Accordingly, inhibiting TGFβ signaling has the potential to counteract the immunosuppressive milieu and boost CAR T-cell effector functions. Upon binding of TGFβ to TGβRII, TGβRI is recruited, phosphorylated, and activated to phosphorylate the downstream mediators, Smad2 and Smad3, which further coupled with Smad4, the latter which subsequently translocate to the nucleus, and modulates transcription of several genes such as those involved in apoptosis, extracellular matrix neogenesis and immunosuppression [8]. As TGFβRII is the initiating receptor in the TGFβ signaling cascade and isoforms are not detected yet, it was more reasonable to target it rather than TGFβRI. It has been shown that inhibiting TGFβ signaling via overexpressing dominant-negative TGFβRII can actively improve the antitumor functions of T-cells and CAR T-cells in a competitive manner to WT counterpart [9, 10]. Moreover, a clinical trial (ClinicalTrials.gov: NCT03089203) testing the safety and efficacy of the dn TGFβRII in prostate specific membrane antigen (PSMA)-specific CAR T-cells, recently reported on relapsed and refractory metastatic prostate cancer [11]. All these data suggest a potentially methodical improvement by using CRISPR/Cas9 technology to knock out endogenous TGFβRII expression to generate engineered TGFβ-resistant CAR T-cells to cope with the immunosuppressive environment within the tumor.

To address CRISPR/Cas9-driven TGFβRII KO CAR T-cell therapy in solid tumors, this study entailed two cancer associated antigens which are not or rarely expressed on normal tissues. Claudin 6 (CLDN6) is an oncofetal tight junction protein which is frequently expressed on various human solid cancers such as ovarian cancer cells [12, 13]. The other tumor antigen is taken from mesothelin (MSLN), a glycosylphosphatidylinositol-anchored cell surface protein that is expressed at low levels on normal mesothelial cells [14]. However, it is vastly overexpressed on a wide range of cancer tissues of epithelial origin including ovarian cancer [15].

In the current study, we hypothesized that the combination of a MSLN or CLDN6 CAR specific T-cells and a knockout of TGFβRII will unleash CAR T-cell functions even under immunosuppressive conditions applied in vitro. We could successfully eliminate expression of the TGFβ receptor II in human CD4 and CD8 T-cells using the CRISPR/Cas9 genome editing system. After introducing the CAR coding region via electroporation of in vitro transcribed RNA (IVT RNA) or retroviral transduction into the TGFβRII KO T-cells, these engineered TGFβRII KO CAR T-cells outperformed WT CAR T-cells by means of proliferation, cytotoxicity and cytokine secretion in the presence of exogenous TGFβ. Moreover, they were also able to resist the immunosuppressive effect of autologous iTregs more robustly in comparison to WT CAR T-cells. They also demonstrated improved function and less exhaustion after multiple rounds of antigen stimulation and showed no activation induced exhaustion, which eventually, ended up with better cytotoxicity after second or third antigen exposures.

Cell lines and culture conditions

Human cell lines, including ovarian cancer NIH-OVCAR-3 (RPMI+20% FBS), SK-OV-3 (McCoy’s 5a +10 % FBS), cervical cancer HeLa (EMEM+10%FBS), lung cancer COLO-699-N (RPMI+10% FBS), breast cancer c.l. MDA-MB-231 (RPMI+10% FBS), teratocarcinoma c.l. PA1-SC12 (MEM+10%FBS) and HEK-293 embryonic kidney cells (DMEM+10%FBS) have been used in this study. MDA-MB-231 and its lentiviral derivative MDA-MB-231-hCLDN6 (DMEM+10%FBS) were also used in some experiments. The cells were routinely checked for mycoplasma contamination.

Antibodies

CAR Mesothelin surface expression on human T-cells was assessed using primary antibody goat anti-human IgG F (ab’)2 Biotin (BioRad, Hercules, CA) along with secondary conjugate Streptavidin APC (BioRad). The following antibodies were also used in FACS buffer in this study: anti-PD1-PE (Biolegends 329906), anti-CCR7-Alexa-fluor 647 (BD 560921), anti-CD8-FITC (BC A07756), anti-CD8-BV421 (BD 562428), anti-HLA-A2-FITC (BD 551285), anti-CD86-PerCp-Cy5.5 (BD 561129), anti-CLDN6-Dylight 650 (IMAB027), anti-idiotype-IMAB027- Alexa-fluor 647 and 7AAD (BC A07704). Mesothelin expression was detected using the PE conjugated anti mesothelin antibody (R&D system FAB32652P). Acquisition and analysis of all samples were performed on a BD FACS CantoI/II (BD Biosciences, San Jose, California) and FlowJo software (v7.6.1).

T-cell isolation and activation and human iDC generation

PBMCs were isolated from buffy coats from healthy donors (blood transfusion center at University Medical Center (UMC) Mainz, Germany) by Ficoll®-Hypaque (GE Healthcare) density gradient centrifugation. Monocytes were isolated using anti-CD14 microbeads (Miltenyi Biotec) and CD8 and CD4 cells were isolated using anti-CD8 and anti-CD4 microbeads, respectively (Miltenyi Biotec) according to the manufacturer’s protocol. Immature DCs (iDCs) were differentiated from CD14⁺cells in RPMI 1640 GlutaMAX™, 50 IU/mL penicillin, 50 μg/mL streptomycin, and 10% (v/v) human AB serum (denoted huRPMI), supplemented with 1,000 IU/mL recombinant human (rh) GM-CSF and 1,000 IU/mL rh IL-4 (Miltenyi Biotec) twice in 5 days. For T-cell activation, 2 × 10⁶ / ml of isolated T-cells were cultivated in 24 well tissue culture plates precoated with 2 μg/ml anti-CD3 antibody (clone OKT3; Bioxcell) in huRPMI supplemented with 100 IU/mL IL-2 for 2 to 3 days. Cells were then harvested, washed and resuspended in huRPMI with 50 IU/mL IL-2 and either rested or immediately submitted to further processing steps.

In vitro transcription

The genetic construct encoding the MSLN specific chimeric antigen receptor (CAR) containing fully human anti MSLN scFv, CD8α hinge/transmembrane region, and 41BB and CD3ε cytosolic signaling domains was generated according to the US patent 9272002 B2 and synthesized chemically. The KOZAK/coding region was subcloned into pST1 [16]-derivative MP3 553 pST1-deltaEar1-hAg-SmaI-2hBgUTR-A30L70 which is optimized for RNA in vitro transcription concerning polyA-length and composition. The codon optimized full length ORF of human mesothelin (NP_005814.2) was also subcloned into the same vector. For in vitro transcription, 10 μg of plasmid preparations were digested with SapI to be linearized and then purified using QIAquick PCR purification kit (Qiagen). The linearized plasmids were subjected to T7 RNA polymerase reaction in the presence of all four ribonucleotides and D2 cap for 3 hours at 37°C. Subsequently, template DNA was fully digested using Turbo DNase. RNA was purified using components of RNAeasy Mini kit (Qiagen) and eluted into RNase-free water. IVT-RNA concentration was adjusted to 1 μg/μl and stored at -80°C. The quality and integrity of the RNAs were confirmed using 1.5 % MOPS gel. IVT-RNAs encoding the second generation CAR 8BBz CLDN6 and CLDN6 were prepared same way [13].

Design and construction of CRISPRs

Single guide RNAs (sgRNA) specific for exon 2 of TGFβRII was designed using the CRISPR design tool provided by Synthego (https://design.synthego.com/#/) and chemically synthesized as O-methyl-protected derivatives. Three highest-ranking gRNAs of top ten with lowest mismatch score from both strands of human TGFβRII (Gene ID: 7048, NCBI) were selected comprising the following sequences: gRNA-3: GAAGCCACAGGAAGUCUGUG, gRNA-5: AUGAUAGUCACUGACAACAA, and gRNA-7: GCAGGAUUUCUGGUUGUCAC. The coding sequence of Cas9 was subcloned from pCAG-T3-hCAS-pA (Addgene #48625) into pST1 and IVT-RNA was prepared as described before.

Generation of TGFβRII^- T-cells

T-cells were washed two times with OPTI-MEM (Invitrogen) and resuspended in serum free OPTI-MEM at a final concentration of 6–12 × 10⁷ cells/mL. Afterwards, 100 μL of cell suspension was mixed with RNAs: 10 μg of Cas9 IVT-RNA and 5 μg of gRNA 3/5/7 were electroporated in a 2-mm cuvette (VWR) using a PA-4000 (Harvard Apparatus BTX) at 400 V voltage and 2 ms single pulse length. Following electroporation, the cells were immediately transferred to prewarmed T-cell culture media supplemented with IL2 (50 IU/mL) and incubated at 37°C and 5% CO2 for 5 days.

Antigen and CAR surface expression via IVT-RNA

Wild type or TGFβRII KO T-cells were washed two times with serum free X-vivo 15 and then resuspended in the same medium to the final concentration of 4 × 10⁷ cells/mL. Afterwards, 250 μL of the cells were mixed with 15 μg of IVT-RNA CAR MSLN or 10 μg of IVT-RNA CAR CLDN6 in a 4-mm cuvette (VWR) using a PA-4000 (Harvard Apparatus BTX) at 495 V and 9 ms. Following electroporation, the cells were immediately transferred to prewarmed culture media and incubated at 37°C and 5% CO2 for 20 hours prior to functional assays. iDCs were treated the same before electroporation and then adjusted to a cell density of 2 × 10⁷ cells/mL Cells were then electroporated at 300 V for 12 ms with 2 μg IVT-RNA CLDN6 or 10 μg MSLN. For luciferase based cytotoxicity assay the target cells were co-electroporated with 5 μg of luciferase IVT-RNA.

Transduction and CRISPR/Cas9 engineering of the human T-cells

For long term cytotoxicity assay, it was necessary to stably express CAR constructs in T-cells. MACS-isolated human CD8⁺ from fresh PBMCs were pre-activated by Dynabeads™ Human T-Activator CD3/CD28 (Gibco) in a beads to CD3+ T-cell ratio of 1:1, in the presence of 100 IU/ml IL-2. 48 hours after bead-activation, cells were seeded and incubated on RetroNectin (Takarabio) pre-coated plates (200 mg of 20mg/ml) saturated with CAR gamma-retroviral supernatants by centrifugation (30 min, 15 °C, 1500 rpm) to obtain an multiplicity of infection (MOI) for T-cell : viral particle ratio of 1. After extra 48 hours, pre-activation Dynabeads™ Human T-Activator CD3/CD28 were removed from culture and cells were electroporated for Cas9 mRNA and TGFβRII-specific gRNAs as described before. Non-transduced T-cells served as controls. Heterologous CAR expression on transduced human T-cells was assessed via flow cytometry.

Gene disruption efficiency assay using T7 endonuclease I assay, Sequencing and TIDE assay

Five days after electroporation with gRNA and Cas9 mRNA, genomic DNA was extracted from the cells using QIAmp DNA mini kit (Qiagen) according to the manufacturer’s instructions. The genomic regions flanking the sgRNA target site in the TGFβRII gene were PCR amplified with the following primers: TGFβRII forward: 5’-AGAAAGTGGACCTTATGACAACCA, and TGFβRII-reverse: 5’-AGGAGGTGTCGGTTAAATGACTAC using Q5 high fidelity DNA polymerase (NEB). The PCR products were either purified and Sanger sequenced with TGFβRII-sequencing primer : 5’-TCTGATGTGAAGGAATTATTTTGCCT and then subjected to TIDE analysis using the online tool http://tide.nki.nl (Analyses were performed using a reference sequence from a Cas9 mock-electroporated sample) or subjected to T7EI Nuclease (NEB) assay as previously described. Briefly, the PCR products were first heated up to 90 °C to be denatured and then the temperature gradually decreased to 10 °C to reanneal the product. The mixtures were then subjected to T7E1 digestion for 15 minutes which recognizes mismatches, and finally analysed on a 2 % agarose gel.

Luciferase, spheroid and impedance based cell lysis assays

For luciferase based cytotoxicity assay, WT CAR T-cells or TGFβRII KO CAR T-cells were cocultured in triplicates with the Ag and luciferase expressing targeT-cells at the indicated E:T ratio 20 hours after electroporation in white Nunclon Delta surface 96 well plates. Three hours after setting up the coculture, 50 μl of the substrate solution, 1mg/ml Luciferin (BD, moonlight D-luciferin) and 50 mM HEPES, was added to each well. Triton-X100 (0.25% f.c.) was added for full lysis control. The bioluminescence emission was recorded using Tecan Infinite 200 reader at indicated time points and the cytotoxicity was calculated as follows:

L_sample : Luminescence mean by sample lysis

L_max : Luminescence mean by maximal lysis

L_min : Luminescence mean by spontaneous lysis

To mimic the 3D nature of tumors, spheroid based cytotoxicity assay was performed using the Incucyte live cell imaging system. For generating the spheroids, tumor cell lines were electroporated with eGFP mRNA and seeded in spheroid plates (Corning #7007) for 24 hours. After 24 hours, the generations of spheroids and fluorescence emissions were confirmed using the Incucyte, and WT CAR T-cells or TGFβRII KO CAR T-cells were added to the corresponding wells, and reduction of the fluorescence intensity was monitored over time. The data were analyzed using Incucyte software and the background was subtracted using the Top Hat algorithm.

An impedance‐based tumor lysis cell culture system (xCELLigence, ACEA Biosciences) was used to assess the long-term T‐cell cytotoxicity in real-time. By means of an electrode‐bottomed plate, the device measures the electrode impedance of adherent target cells which corresponds to cell viability, and reports it using a unitless parameter called Cell Index (CI). Cell lysis leads to detachment of target cells decreasing CI over time. Target cells were seeded on 96‐well electrode-bottomed microtiter plates (E-Plate® 96) at 2 × 10⁴ cells/100 μL/well. After 20 to 24 hours, right before when CI starts to plateau, the effector cells were added at indicated E:T ratios and the CI was recorded every 15 min. To correct for diverging growth curve properties on a 96-well plate (‘edge effects’), CIs of any time point were first normalized to the CI (NCI) shortly before effector cells were added to every well and averaged over replicates. Specific lysis was calculated via the following formula taken from RTCA software:

NCI_sample : Normalized cell index mean by sample lysis

NCI_max: Normalized cell index mean by maximal lysis

NCI_min : Normalized cell index mean by spontaneous lysis

Repetitive antigen stimulation assay

TargeT-cells were seeded on Xcelligence plates (2 × 10⁴ cells/100 μL/well), and after 20 to 24 hours, WT or TGFβRII KO CD8+ T-cells, which were retrovirally transduced to express a CLDN6 specific CAR were added at an E:T ratio of 5:1 in the presence or absence of TGFβ. Cytotoxicity was monitored for 48 hours in real time. Subsequently, CAR T-cells were collected from wells, washed, counted again and added to a new Xcelligence plate containing previously seeded target cells the same way as before. The amount of cell lysis was monitored again for 48 hours, and the same procedure repeated one more time. The concentration of TGF-β1 was maintained at 5 ng/mL in the treatment group.

Proliferation

Either WT CAR T-cells or TGFβRII KO CAR T-cells were labeled with 0.8 μM carboxyfluorescein diacetate succinimidyl ester (CFSE, Invitrogen) or 10 µM eBioscience™ Cell Proliferation Dye eFluor™ 450 (CPD450) and cocultured with Ag mRNA-electroporated iDCs at an E:T ratio of 5:1 in round-bottom 96 well plates with different doses of TGF-β1 (carrier-free; R&D Systems). An aliquot of culture supernatants was harvested after 24 h for cytokine analysis.

After 5 days of coculture T-cells were stained with anti-CD8 or anti-CD4 antibody and the reduction of CFSE-staining as readout for cell divisions measured using the high through put sampler (HTS) implemented on a FACS canto II device.

Cytokine enzyme-linked immunosorbent assay (ELISA)

WT CAR T-cells or TGFβRII KO CAR T-cells were cocultured with Ag mRNA-electroporated iDCs or cancer cell lines at different E:T ratios in round-bottom 96 well plates in a final volume of 200μl. After 24h, 100 ul of supernatant was collected and frozen down to -80 °C for analysis later on, or 1:2 – 1:10 dilutions in assay diluent were assayed immediately by incubating for 3 h at 37°C on high protein binding 96-well plates precoated with a cytokine-specific capture antibody. After repetitive washing immobilized cytokines (IFN-γ) were detected with a biotinylated detection antibody/streptavidin-HRP-conjugate after addition of the substrate NBT. Color development was photometrically quantified on TECAN Sunrise ELISA reader system and quantified by calculation of μg/ml via a cytokine standard developed in parallel. The supernatants were assayed for producing human IL-2 and IFN-γ using human ELISA kit (Invitrogen), while Granzyme B (GrB), TNF-α and GM-CSF were quantified by the DuoSet ELISA Development Kit (R&D Systems).

iTreg generation in vitro suppression assay

CD4⁺T-cells were positively selected from fresh PBMCs using CD4 microbeads (Miltenyi-Biotec) according to the manufacturer’s protocol and rested for 3 hours. Cells were then plated in 24 well plates precoated with 5μg/ml anti-CD3 antibody (clone OKT3; Bioxcell) at 2x10⁶ cells/well in serum-free X-Vivo 15 medium (Lonza) supplemented with 1 μg/ml soluble anti-CD28 antibody (Biolegend, ultra LEAF grade) and 100 IU/ml IL-2. Cells stimulated with only these reagents served as control. For iTreg generation, 5 ng/ml of TGF-β1 (carrier-free; R&D Systems), 10 nM of all trans retinoic acid (ATRA) (Sigma-Aldrich) and 100 ng/ml of rapamycin (Calbiochem EMD Millipore ) were added to the culture media. Cells were incubated for 6 days at 37°C/5% CO2 in an incubator. Thereafter, CD4+ T-cells being committed to differentiate into induced Tregs (iTregs) were washed and rested for two to three days in X-Vivo 15 medium with 50 U/ml IL-2. For setting up the suppression assay, iTregs were washed again and resuspended in fresh medium without any IL-2. The responder (Tresp) cells were either WT CAR T-cells or TGFβRII KO CAR T-cells. Tresp were labeled with 10 μM CPD-450 as described before and the coculture set up as followed: In each well of round-bottom 96 plate, constant number of Tresp cells (5 × 10⁴) and Ag expressing iDCs as target cells (1 × 10⁴) were coseeded and additionally, cocultivated with suppressive iTregs or activated CD4+ T-cells as negative control at different ratios (2:1,1:1, 0.5:1 and 0.25:1). Cells were cultured for 3 to 4 days and suppression in proliferation was analysed by flow cytometry.

MSLN and CLDN6 specific CAR T-cells recognize and kill cognate antigen expressing tumor cell lines.

In this study, we focused on CAR T-cells specific for the tumor antigens mesothelin and claudin 6 (Fig. 1A), which are highly expressed on tumor cells but rarely detected on normal cells. We either used antigen overexpressing cell lines, HeLa (Fig. 1B i) and OVCAR-3 (Fig. 1B ii) for MSLN-specific antigenicity, PA-1 SC12 (Fig. 1B v) and OVCAR-3 (Fig. 1B vi) for CLDN6-reactivity or exogenously overexpressed the antigen on the cell surface of iDCs (MSLN and CLDN6) (Fig. 1B iii & vii) or on antigen-negative cancer cell lines (MDA-MB-231) (Fig. 1B vi) via IVT-RNA electroporation.

We activated CD4+/CD8 + T-cells and transfected them with MSLN (15 µg) and CLDN6 (10 µg) CAR encoding IVT RNAs. At this high dose, we could monitor around 50 % CAR expression for both antigen specificities (Fig. 1C i/D i).

To confirm that the CAR MSLN T-cells are functional in vitro we performed multiple assessments. In the first step, IFN-γ secretion was examined against differenT-cell lines: CAR MSLN T-cells secreted high level of IFN-γ towards MSLN expressing cell lines, up to 4000 pg/mL in case of OVCAR-3 and 1500 pg/mL in case of HeLa cell line as target cell (Fig. 1C ii). There was no significant secretion of this cytokine against the negative control cell lines SK-OV-3 and COLO-699-N. Furthermore, cell cytotoxicity was evaluated by means of a 3D culture spheroid lysis assay (Fig. 1C iii). Solid phase spheroid cells reflect the in vivo situation in some aspects such as actively dividing tumor cells at its boundaries with optimal nutrients provision, and at its core tumor cells becoming apoptotic or necrotic [17]. However, it does not embrace immunosuppressive and angiogenetic effects in TME. Our data confirmed that the CAR MSLN T-cells successfully kill the tumor spheroids even at a low E:T ratio of 1:1, which could achieve almost 100% killing in 24 hours as opposed to mock T-cells. Decrease of fluorescence in negative controls reflects the degradation of GFP encoding mRNA over time. Conclusively, these data proved cytokine secretion and cytotoxic function of CAR MSLN T-cells.

To assess CAR CLDN6 functionality, CAR CLDN6 T-cells were cocultured with IVT-RNA electroporated iDCs expressing CLDN6 heterologously at increasing doses for an E:T ratio of 5:1 to quantify secreted IFN-γ in an ELISA. The amount of detected cytokine ranged between 1000 pg/ml for 2 µg electroporated Cl6 and 100 pg/ml for 0.02 µg electroporated CLDN6 (Fig. 1D ii), and hence, decreased dose-dependently.

For the impedance based cytotoxicity assay, we electroporated the SK-OV-3 3 cell line with 2µg CLDN6 RNA and seeded them on xcelligence plates. After 24 hours, the CAR CLDN6 or the mock T-cells were added at an E:T ratio of 5:1 and the impedance changes were recorded over time. Successful killing of CLDN6⁺ SK-OV-3 3 cells by CAR CLDN6 effector T-cells (70%) was confirmed, while no relevant cytotoxicity was observed for mock T-cells (Fig. 1D iii).

We also evaluated the proliferation of CAR CLDN6 T-cells applying a CFSE dilution based assay in a dose dependent manner. These CAR T-cells divided strongly up to a frequency of 80%, not only in the presence of a high dose of heterologously expressed CLDN6 in iDCs (2 ug), but also at a dose as low as 0.02 ug CLDN6 (70%; Fig. 1D iv). Notably, no proliferation was detectable in the presence of mock-electroporated iDCs. In conclusion, our data confirmed that both CARs specific for MSLN and CLDN6 elicited superior effector functions against antigen expressing tumor cell lines or iDCs.

Exogenous TGFβ impairs CAR T-cell proliferation in vitro

Due to the fact that TGFβ is one of the key regulator of the immune system in the tumor microenvironment, which vastly suppresses CAR T-cell function [9], we hypothesized that one of the hurdles in solid tumor CAR T-cell therapy arise from high levels of TGFβ in TME. To test this hypothesis, we performed a series of in vitro tests to find out if exogenous TGFβ can exert a suppressive effect on our CAR T-cells specific for 2 different tumor antigens. IVT electroporated iDCs (CLDN6/ MSLN) were cocultured with CAR CLDN6 or CAR MSLN T-cells at increasing doses of TGFβ. A broad range of exogenous TGFβ added (5–20 ng/ml) could significantly suppress CAR T-cell functions in terms of cytokine secretion (Fig. 2A) and proliferation (Fig. 2B) which is consistent with previous reports. Secretion of IFN-γ, the most prevailing immunostimulatory T-cells’ cytokine, is very susceptible to even the lowest dose of TGFβ added, dropping to less than 40 % of the IFN-γ secretion in absence of TGFβ. In line to that, proliferation of both MSLN and CLDN6 specific CAR T-cells was reduced to less than of 50 % of their native proliferation (i.e. absence of TGFβ) in the presence of even very low dose of TGFβ (5ng/ml). Noteworthy, the suppressive effect of TGFβ do not only last for short-term incubation times (< 24h) as it is demonstrated here for an IFN-γ ELISA, but is also obvious for long-term proliferation assays (5–6 days). In conclusion, these data demonstrate that TGFβ is a potent inhibitor of CAR T-cells, regardless of their antigen specificity.

Deletion of TGFβ RII via CRISPR/Cas9 system

We prompted us to assess whether genomic disruption of TGFβRII in CAR T-cells will counteract the aforementioned functional impairment of CAR T-cells in the presence of exogenous TGFβ. To achieve this purpose, we designed a 2-step protocol comprising CRISPR/Cas9 based gene knock out of the TGFβRII locus and subsequent CAR IVT-RNA electroporation into those genomically edited primary human T-cells (Fig. 3A). The RNA-guided Cas9 nuclease from the microbial CRISPR adaptive immune system is an efficient genome editing tool which consists of nuclease Cas9 and a single-guide RNA (sgRNA) targeting a 20-bp region of the genomic region of interest [18]. We used the Synthego online tool to design sgRNAs and selected three gRNAs from the top ranked suggested sgRNAs on both strands with at least 50 nucleotides distances (Fig. 3B). The Synthego online tool uses the Doench et al [19] scoring algorithm to select efficient sgRNAs and also ranks the sgRNAs based on the numbers of genomic off targets. Number of potential off target sites for one, two and three mismatches was zero for gRNAs 3/7, while in the case of gRNA5, four off targets emerged with three mismatches. To combine the knock out procedure and CAR expression, briefly, OKT3 activated T-cells were electroporated with Cas9 mRNA alone (Cas9 control), or Cas9 and chemically synthesized O-methyl protected sgRNA targeting TGFβ RII exon 2. Five days later, TGFβ RII ablation was checked using genomic analysis techniques by means of a T7 endonuclease I assay and Sanger sequencing. Cells were subsequently electroporated with saturating amounts of IVT mRNA encoding the anti-MSLN or anti-CLDN6 CAR (Fig. 3A).

To determine the knock out efficiency, genomic DNA was extracted from the cells (Cas9 only and Cas9 with gRNAs 3, 5 or 7) and was submitted to PCR amplification using PCR primers flanking the sgRNA targeting region. An aliquot of the PCR products was subjected to T7 endonuclease I restriction and then run on an agarose gel (Fig. 3c).

T7 endonuclease I recognizes and cleaves mis-matched DNA, which could lead to extra bands on the gel in case of indel formations. The PCR product from control cells and the three gRNAs treated cells were submitted to digestion by T7E1 enzyme. While there were no extra bands in the control, all gRNA treated groups exhibited extra bands which indicates indel formations (Fig. 3C). As outlined in Fig. 3B, each gRNA targets nearby but different genomic sequences of the TGFβRII gene and hence, taking into account to use identical PCR primers, the restriction pattern of T7E1 ended up with variably sized restriction products for each gRNA visible on the gel. The PCR products were also delivered for Sanger sequencing and the data were analyzed for indel frequencies applying a decomposition technique. Base ambiguities commence after base 4 of gRNA7 (5’-GTGA-A/C…), which is consistent with the postulated genomic cut site of Cas9 (Fig. 3D). Again, results confirmed indel formations in all gRNA treated groups (Fig. 3D/E). Although gRNA3 was prone to form less indels in comparison to the two other gRNAs (Fig. 3E), we did not exclude it from our further experiments so as to check if even a lower level of genomic TGFβRII knock out might also have a measurable effect on CAR T-cell functions. In summary, these data exhibited the successful generation of insertions/deletions (INDELs) in the TGFβ RII gene locus. We were able to demonstrate gene ablation to similar degrees for the 3 scrutinized gRNAs in both, CD8 + and CD4 + cells, respectively (Fig. 3E).

TGFβ RII disruption in CAR T-cells enhances their in vitro effector functions

To determine the effect of TGFβRII deficiency on CAR T-cell function, we assessed TGFβRII KO CAR MSLN and CAR CLDN6 T-cells in different assays in vitro. Due to limited KO efficacy, these experiments were done on bulk populations that contained both edited and non-edited cells. As an essential prerequisite for comparison of KO CAR T-cells with WT CAR T-cells, gene ablation of TGFβRII must not interfere with IVT-RNA - mediated CAR expression in T-cells. Indeed, we observed very similar frequencies of CAR expression on T-cells (Fig. 4A): 50% CAR expression could be observed for both, CAR-MSLN electroporated T-cells and TGFβRII KO CAR-MSLN T-cells. Similar to that, we also found up to 70 % CAR expression in electroporated T-cells for CAR CLDN6 irrespective of the genomic editing step. Additionally, we analyzed proliferation of WT or KO CAR T-cells following electroporation in the absence of exogenous TGFβ to determine whether deletion of the TGFβRII gene has any impact on proliferation and/or survival of CAR T-cells. In most tests, we did not monitor any marked alterations in proliferation between WT and TGFβRII KO CAR T-cells and analysis among multiple donors did not result in a statistically elevated difference between WT and KO groups when the latter group was averaged over the 3 different gRNAs (white bars in Fig. 4B, and data not shown). Antigen independent expansion or cytokine secretion of KO CAR T-cells was absent leading to the conclusion that deletion of the TGFβRII does not result in immortality (black bars in Fig. 4B and 5 ).

Again, TGFβ induced reduction of cell proliferation by more than a factor of 2 in WT CAR T-cells. Intriguingly, proliferation rates were restored in CD8 + and CD4 + TGFβRII KO CAR MSLN or CAR CLDN6 T-cells following stimulation with antigen presenting iDCs even in the presence of escalating doses of exogenous TGFβ (Fig. 4B). Of note, for TGFβRII KO CAR MSLN T-cells we still observed a small but steady decline of dose rate - dependent proliferation for 2 out of 3 gRNAs tested. This may result from a higher fraction of non-edited CAR T-cells in bulk CD8 + T-cells used in the assay here, the former which is still susceptible to TGFβ. We also assessed the cytolytic potential of KO TGFβRII CAR T-cells specific for MSLN or CLDN6 against antigen loaded iDCs (Fig. 4C) in a bioluminescence cytolysis assay. However, in contrast to the proliferation and cytokine secretion results discussed before the killing efficiency of these KO CAR T-cells is not affected compared with the WT control.

Nonetheless, when compared to WT CAR-T-cells, TGFβRII KO CAR-T-cells released equal amounts of IL-2 (Fig. 5A, S1A), IFN-γ (Fig. 5B, S1B), TNFα (Fig. 5C, S1C), GM-CSF (Fig. 5D, S1D)-cytokines, and GranB (Fig. 5E,S1E) (tested just for one KO group/gRNA7) when they were cocultured with iDCs expressing the cognate antigen in the absence of exogenous TGFβ. This cytokine release was dependent on CAR expression and non-electroporated T-cells (mock) failed to release cytokines in the presence of antigen positive cells (data not shown). Importantly, WT CAR-T-cells lost their ability to secrete cytokines in the presence of exogenous, TGFβ to varying extents (Fig. 5) in the order IFN-γ > GM-CSF > GranB > TNF-α > IL-2 in a TGFβ dose-independent manner. Contrary to that, TGFβRII KO CAR MSLN or CAR CLDN6 T-cells reset the immunusuppressive effect of TGFβ on cytokine secretion almost completely irrespective of the amount of suppression observed for WT CAR T-cells. Secondly, the antagonizing effect of TGFβRII KO CAR MSLN or CAR CLDN6 T-cells was on the whole independent of the dose of exogenous TGFβ added. We postulate that in general, a larger fraction of edited CAR T-cells being present in the bulk population dominate the fraction of non-edited CAR T-cells in the net outcome of function. This means to expect rather a gradual decrease of cytokine secretion in TGFβRII KO CAR T-cells, which is true for most sample groups. However, a steady TGFβ dose rate-dependent increase of GM-CSF and TNF-α secretion became only evident for KO TGFβRII CAR MSLN T-cells. This may be here due to the ratio of edited versus non-edited T-cells, the sensitivity of these cytokine secretion pathways towards TGFβ, and the somewhat lower efficacy of CAR MSLN compared with CAR CLDN6.

In total, these results suggest that TGFβ RII disruption can antagonize in all three KO groups diverse long-term and short-term functional defects induced in WT MSLN or CLDN6 4-1BBζ CAR T-cells treated with exogenous TGFβ. However, our experiments did not reveal any effect of exogenous TGFβ in short term killing assays (4 hours) against immunostimulatory target cells such as iDCs, neither for WT nor KO CAR T-cells.

TGFβ receptor II disruption augments long term cytotoxicity

Several reports showed an inhibitory effect of TGFβ on the cytotoxicity of T-cells and CAR T-cells cells [20–23]. However, we could not reproduce any suppression in short term cytotoxicity assays against iDCs. Hence, we addressed the question whether on long term exposure, TGFβ can hinder the killing function of the CAR T-cells taking into account in particular the chronic prevalence of a suppressive milieu in TME over time in patients. For this, we switched to stably CAR modified T-cells to circumvent transient expression of CARs based on IVT-RNA. Hence, we decided to use virally transduced T-cells and target cells (Fig. 6A). Transduced T-cells were then evaluated for CAR expression (Fig. 6B), viability and TGFβRII KO efficiency. Cytotoxicity was measured using the impedance based technique on an Xcelligence device using adherent CLDN6 + PA-1 Sc12 cell line as target and WT and KO TGFβRII CAR CLDN6- T-cells as effectors. Cells were incubated at an E:T ratio of 5:1.

WT and KO CAR CLDN6 T-cells were not meaningfully different in their cytotoxic function in the absence of TGFβ (Fig. 6C, red curve). However, in the presence of TGFβ, the killing efficacy of WT CAR CLDN6 T-cells was significantly impaired over the entire time range (72h, green curve) to a steady-state level. Remarkably, although all three KO CAR CLDN6 T-cells revealed decreased cytotoxicity to the same extent within the first five hours after coculture setup with target cells, their cytolysis potency recovered in the presence of TGFβ and aligned with the level of cytolysis monitored over time for the non-TGFβ-treated controls (Fig. 6C/D). The initial reduction could be attributed to an immediate suppressive effect of TGFβ captured here in real-time for bulk WT/KO T-cells against immunodeficient tumor cells in contrast to the results shown for immunostimulatory iDCs (Fig. 4C). After this lag-phase TGFβRII KO CAR T-cells became resistant to the TGFβ effect and caught up with non-TGFβ treated CAR T-cells in their cytolytic efficacy. Hence, we postulate that CAR T-cells can indeed be suppressed by TGFβ also in their cytotoxic function as resolved here in a real-time setting. Importantly, this can be reverted with TGFβRII KO CAR T-cells in the long run.

Genomically edited TGFβ unresponsive CAR T-cells can escape control by induced regulatory T-cells.

TGFβ not only commits naïve CD4 cells to differentiate into Tregs, but this cytokine also represents one of the principle mechanisms by which Tregs suppress their primary targeT-cells, namely effector T-cells [24–26]. It has been shown in the past that T-cells which do not respond to TGFβ are able to escape control by regulatory T-cells [27]. It is well known that Tregs are highly abundant in TME, especially in tumors with high level of TGFβ secretion, so we prompted us to verify whether TGFβRII KO CAR T-cells were not only able to withstand TGFβ but also to resist the suppressive effect of Tregs (Fig. 7A). For such experiments, we were challenged to generate Tregs ex vivo from PBMCs in sufficient numbers which were referred to as induced regulatory T-cells (iTregs). The detailed protocol for generating iTregs has been described elsewhere [28]. In brief, CD4 + cells were activated with anti CD3, anti CD28 and IL2. The CD4 + cells which were treated this way represent activated CD4 + T-cells as negative control for immunosuppression. For differentiation into iTregs, rapamycin, retinoic acid and TGFβ were subsequently added to the culture medium. T-cells were activated for up to 6 days, and then analyzed for FOXP3 and CD25 expression to confirm their iTreg phenotype (Fig. 7B). One day before setting up the coculture WT and TGFβRII KO T-cells were electroporated with CAR MSLN (Fig. 7C) or CLDN6 (Fig. 7D) IVT-RNAs and iDCs were electroporated with the respective antigen encoding IVT-RNAs. Since we aimed at demonstrating cessation of the suppressive effect of induced regulatory effector T-cells in a proliferation assay, responder CD8⁺ T-cells were stained with CFSE before seeding. For setting up the coculture, fixed numbers of iDCs and WT or KO CAR T-cells were coseeded and iTregs were added for different ratios to CAR T-cells (2:1, 1:1 and 0.5:1; Fig. 7C/D). The responder groups comprised beside the WT CAR T-cells as reference 3 different TGFβRII KO CAR Tcell groups each treated with one of the CRISPR/Cas9 gRNAs 3, 5, or 7, respectively. As positive control we included the addition of exogenous TGFβ in the absence of iTregs, to confirm on the one hand that WT CAR T-cells are susceptible to suppression and on the other hand that TGFβRII KO CAR T-cells generated ex vivo are resistant to the anti-proliferative effect of exogenous TGFβ (Fig. 7C/D, second outmost left). Eventually, WT and KO CAR T-cells elicited comparable rates of proliferation in the absence of exogenous TGFβ (Fig. 7C&D outmost left). Activated CD4 + T-cells turned out to be not able to suppress WT and TGFβRII KO CAR T-cells. Intriguingly, in vitro generated iTregs can inhibit proliferation of WT CAR T-cells even at the lowest iTreg to CAR T-cell ratio, ranging from excess 2:1 down to 0.5:1. Most importantly, although iTregs can also inhibit the TGFβRII KO CAR T-cells a little, the suppressive effect is less pronounced in a iTreg dose-dependent fashion compared to that in case of WT CAR T-cell. The remaining suppressive effect in 3 gRNA treated groups may at least in part be explained by the bulk T-cell populations used here, comprising unedited and hence TGFβ-responsive WT CAR T-cells and TGFβRII KO CAR T-cells in each group. The suppressive effect is most likely due to TGFβ produced endogenously by the induced regulatory T-cells and secreted for a paracrine effect because we solely targeted TGFβRII via CRISPR/Cas9 in responder T-cells. Since iTregs have not been equipped with CLDN6 or MSLN-specific CARs, iTreg/iDC*Ag cell/cell contacts are highly unlikely to occur and to contribute to the suppressive effect towards responder T-cells observed here [29].

TGFβRII KO rescues CAR T-cell exhaustion induced by TGFβ

Finally, we explored if TGFβ is also able to foster CAR T-cell exhaustion characterized by decreasing functional responsiveness, using a repetitive antigen stimulation assay, and whether the KO of TGFβRII on CAR T-cells are able to prevent this counter-regulatory effect. In a series of experiments, we took advantage of the impedance based cell killing assay: For this, stably modified CAR T-cells by means of retroviral transduction were a prerequisite in long term restimulation experiments. CAR T-cells were cocultured with the cell line OCVAR3 which expresses CLDN6 endogenously at an E:T ratio of 5:1.

In the first (Fig. 8 Ai) and second (data not shown) round of stimulation TGFβ revealed initial suppression within a few hours (Fig. 8 Aii/Aiii) on cytotoxicity, but was not able to mount a long-lasting suppressive effect on the cytotoxicity of the CAR T-cells, neither on WT nor TGFβRII KO CAR T-cells, the latter shown for gRNA 5 and 7, respectively. The reduction in cytotoxicity in TGFβ-treated samples was roughly the same for WT and TGFβRII KO CAR T-cells. Between 8 and 16 hours of coculture lysis became complete for both groups. In the course of the third round of coculture (Fig. 8 Bi), TGFβ-untreated WT and KO T-cell groups sustained cytolytic function over time. On the other hand, WT CAR T-cells turned out to be for the first time vastly impaired in their cytotoxic function in the presence of TGFβ over the whole time frame (Fig. 8 Bii): 48 hours after setting up the assay lysis dropped down to less than 50% in comparison to the TGFβ untreated group.

In contrast, TGFβ-treated TGFβRII KO CAR T-cells recovered from a short suppression phase within 16 hours and retained full lysis potency comparable to their related TGFβ-untreated groups lasting till the end of experiment (48 h).

We reasoned to see a suppressive effect of TGFβ on WT CAR T-cells only in round 3 of stimulation because the moderate endogenous expression rate of CLDN6 on ovarian cancer c.l. OVCAR3 prevents premature exhaustion of WT CAR T-cells. This contrasts to the much higher expression seen on teratoma c.l. PA1, the latter which promotes early differentiation into senescent effector T-cells and hence, sensitivity towards TGFβ of WT CAR T-cells already after initial antigen-specific stimulation as outlined in Fig. 6.

To sum up the restimulation experiment, TGFβ exerts a less pronounced prohibitive effect on freshly activated CAR T-cells irrespective of being genomically silenced for TGFβRII expression or not, but affects significantly cytotoxicity of repetitively antigen-experienced, and hence senescent CAR T-cells. Knock out of the TGFβRII via CRISPR/Cas9 turns CAR T-cells, after a short lag-phase, into effector T-cells unresponsive towards TGFβ in the long term and emphasizes this approach in generating more potent long-lived CAR T-cells in immunosuppressive TME.

TGFβ is highly produced by many tumor types including ovarian malignancies [30, 31]. Tumors can promote TGFβ production by tumor microenvironment resident cells such as fibroblasts [32, 33]. TGFβ is a pleiotropic cytokine with diverse effects on cancer cells and the immune system. In premature phases of tumorigenesis, TGFβ acts as a tumor suppressor [34], whereas during progressed tumor immunoediting [35] cancer cells become resistant to the signaling and antitumor activity of this cytokine and in late stages, they gain genomic mutations which turn TGFβ to a tumor promoting agent [7, 36]. On the other hand, TGFβ is a key regulator of immune homeostasis; in the context of T cells, TGFβ can inhibit proliferation, expression of cytolytic gene cytokines such as IFN-γ and Granzyme B and Th1 differentiation and at the same time has a pivotal role in Treg generation [5, 10, 20]. There are also several reports on TGFβ suppressive effects on CAR T-cells functions, in terms of proliferation, cytotoxicity and cytokine secretion [9, 21, 37, 38].

Having in mind that TGFβ is likely to be one of the most important suppressor cytokines of CAR T-cell function, one may take into consideration different approaches to block its effects. Among the alternatives, localized blockade of TGFβ in tumors is not the best option, since tumor cells are not the only source of TGFβ in TME [5]. Although systemic blockade of TGFβ administering small-molecules or antibodies may act in a more efficient way it couldn’t be ruled out to put the patient at risk of autoimmune disease. It should also be noted that TGFβ triggers apoptosis in pre-malignancies, so the systemic inhibition of TGFβ is not a reasonable option as it may confer tumorigenesis in other tissue regions [7].

Among the different possibilities, inhibiting the TGFβ signaling pathway in T-cells per se is an intriguing idea. Recently, a novel TGFβ specific CAR harboring a scFv against TGFβ has been reported which has the capacity of inhibiting endogenous TGFβ signaling and more interestingly converting TGFβ into a stimulus of T-cell growth [39]. Several other groups also attempt different approaches to tailor TGFβ pathway in the context of CAR T-cell therapy so as to improve CAR T-cell function in solid tumors.

Since TGFβRII is the first cellular component in TGFβ signaling, it is reasonable to target this receptor in the first place to block immunosuppressive T-cell signaling. Kloss et al. reported on the overexpression of a dominant negative TGFβRII which lacks the intracellular signaling domain in PSMA specific CAR T-cells leading to improved CAR T-cell function in vitro and in vivo (9). However, this approach still allows for the expression of the wild type TGFβRII and hence, will not abolish TGFβ-mediated signaling in T-cells. Tang et. al. reported that knocking out the endogenous TGFβRII in CAR T-cells could reduce conversion to induced Tregs and prevent the exhaustion of CAR T-cells and led to better in vivo tumor elimination efficacy of CD28 second generation CARs specific for MSLN [21]. However, the authors did not assess, whether TGFβ produced by Tregs endogenously will affect other T-cells’ function, as we could confirm in our work here. In a very recent study, Liu et al [40] using a Cre-lox system, demonstrated that ablation of TGFβRII in CD4 + T-cells promotes tumor tissue healing and halts cancer progression, while in a back to back publication Li et al [41] showed that blocking TGFβ signaling in CD4 + T-cells via Cre-lox system remodels the tumor microenvironment and restrains cancer progression. These approaches thoroughly demonstrate the usefulness to target TGFβRII-signaling to foster T-cell effector functions in several models. However, they did not preclinically assess CRISPR/Cas9 to disrupt TGFβRII as one of the most advanced tool in genomic editing, which already entered clinical phases in other studies [42]. Here, we hypothesized that genomically knocking out the TGFβ receptor via CRISPR/Cas9 in CAR T-cells will improve their functions in a solid tumor context as they will be able to resist the inhibitory effect of TGFβ in the immunosuppressive TME.

One of the most important obstacle is the choice of an optimal antigen [43–45]: Beside lack of tumor specific antigens on tumor cells, the majority of CAR T-cells targeting solid tumors are based on tumor associated antigens, which are highly expressed on tumor cells, but at the same time to some extent on normal tissue, which may lead to ‘on target’ but ‘off tumor’ toxicities. Here, we focused on two ovarian cancer associated antigens which were highly likely not or very rarely expressed on normal tissues. Reinhard et al draw recently the conclusion that CLDN6 is an oncofetal cell-surface antigen with an ideal expression profile for CAR T-cell mediated immunotherapy (Fig. 1A) [13]. To also generalize our strategy we also focused on mesothelin (MSLN) specific CAR T-cells, which has been shown to represent a safe target in several clinical studies [46].

One should keep in mind that despite having CRISPR/Cas9 KO efficacies in the range of 20–60 % in CD4 + and CD8 + T-cells depending on the gRNA used, we conducted our experiments with bulk CAR T-cells encompassing edited and unedited cells. Thus, the beneficial effects in TGFβ resistance should be even more pronounced for homogenously edited or purified T-cell populations. Nonetheless, we could clearly demonstrate that CAR T-cells benefit from knocking out TGFβRII in different aspects of anti-tumor function:

First, genomic inactivation of the TGFβRII signaling pathway does not affect expression of exogenously introduced CAR molecules irrespective of the expression system, which is an essential prerequisite to generate antigen-specific effector T-cells.

Secondly, TGFβRII KO CAR T-cells were able to resist the anti-proliferative effect of TGFβ even at the highest dose of anti-inflammatory cytokine provided. This may not only positively affect the differentiation status and hence, viability and persistence of CAR T-cells but most importantly, the absolute number of therapeutic T-cells at the tumor site: Tumor eradication turns out to be the more efficient the more potent effector cells of a non-senescent phenotype such as central memory T-cells (T_CM) mount an immune response against tumor cells [47]. Moreover, we demonstrated that responder TGFβRII KO CAR T-cells were also able to proliferate in the presence of TGFβ secreted ‘in situ’ by regulatory T-cells, which mimicks, at least in part, the immunosuppressive milieu in TME.

Thirdly, CAR T-cells are able to rescue their cytotoxic function in the presence of exogenous TGFβ, even under conditions of repetitive antigen exposures: Here, we show that CD8 + TGFβRII KO CAR T-cells retain their primary function in the presence of exogenously added excess TGFβ. Antigen-experienced TGFβRII KO CAR T-cells withstand suppression triggered by TGFβ and proved to retrieve full lysis upon successive cycles of restimulation despite their advanced differentiation in direction of a senescent phenotype. This feature is key to maintain a long-lived cytotoxic T-cell population to prevent the outgrowth of clonal tumor escape variants.

Fourthly, TGFβRII KO CAR T-cells were also able to preserve a set of cytokine secretions, whereas WT CAR T-cells were substantially hindered in secreting the proinflammatory cytokines such as TNF-α and IFNγ, the growth factors GM-CSF and IL2, and the cytotoxic mediator Granzyme B in the presence of exogenous TGFβ scrutinized here. In summary, our results support the notion that blocking the TGFβRII signaling pathway by means of its genomic deletion via CRISPR/Cas9 may represent a novel approach to antigen-specifically unleash anti-tumor CAR T-cell function in an otherwise suppressive tumor microenvironment.

It has been well established that TGFβ significantly suppresses the cytotoxic function of CD8 + T cells and also affects CD4 + T-cell differentiation and function by inducing their conversion into regulatory T-cells.

In the current study we prompted us to investigate the effect of a shut down of the TGFβ signaling pathway exclusively in T-cells for two different second generation BBζ CARs specific for MSLN and CLDN6, respectively, taking advantage of the CRISPR/Cas9 genome editing tool. Our study clearly demonstrated that CAR T-cells benefit form knocking out TGFβRII in different aspects of anti-tumor functionality: TGFβRII KO CAR T-cells could resist the anti-proliferative effect of TGFβ even at the highest dose of cytokine applied, and they could preserve their cytotoxic function in the presence of exogenous TGFβ even in repetitive antigen exposure experiments. They could also retain their cytokine secretion profile, comprising TNF-α, IFNγ, GM-CSF, IL2, and Granzyme B. We could also demonstrate that TGFβRIIKO CAR T-cells can withstand the TGFβ-mediated suppressive effect of iTregs ‘in situ’. In contrast, for WT CAR T-cells all effector functions assessed here were significantly impaired in the presence of TGFβ. These observations may emphasize the perspective to apply the genomic disruption of the TGFβRII-mediated signaling pathway as a means of fostering efficacy of CAR T-cell immunotherapy in immunosuppressive tumor entities for future clinical trials.

Chimeric antigen receptor T-cells: CAR T-cells, cell line: c.l., transforming growth factor β: TGFβ, TGFβ Receptor II Knocked out CAR T-cells: TGFβRII KO CAR T-cells, in vitro transcribed: IVT, Mesothelin: MSLN, Claudin 6: CLDN6.

Funding

“This study was financially supported by the institute of Translational Oncology (TRON) at the University Medical Center of the Johannes Gutenberg University Mainz, and grant no. 960404 of the Biotechnology Development Council of the Islamic Republic of Iran and grant no. 96011546 of the Iran National Science Foundation (INSF)”

Acknowledgment

We thank Ugur Sahin for his kind support during this project. In addition, we would like to thank the BioNTech cell and gene therapy (BCGT) team, in particular Petra Oehm, for technical advice and for giving us the opportunity to use the Xcelligence and Incucyte devices.

Authors’ contributions

Study concept and design: KA, RHV, SA and JH. Experiment performing: KA, EM, LJ and HRM. Analysis and interpretation of data: Statistical analysis: KA, RHV, SA, MD, MB and JH Drafting of the manuscript: KA and RHV. Critical revision and fnal approval of the manuscript: RHV,MD,MB and KA. Study supervision: RHV,MD, SA and JH. All authors contributed to the article. All authors read and approved the final manuscript.

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Declarations Ethics approval and consent to participate

The studies does not involve any human participants and animals

Consent for publication

All authors have approved the manuscript for submission.

Porter, D.L., et al., Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia. N engl j Med, 2011. 365: p. 725-733.
Maude, S.L., et al., Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine, 2018. 378(5): p. 439-448.
Neelapu, S.S., et al., Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New England Journal of Medicine, 2017. 377(26): p. 2531-2544.
Newick, K., et al., CAR T cell therapy for solid tumors. Annual review of medicine, 2017. 68: p. 139-152.
Wrzesinski, S.H., Y.Y. Wan, and R.A. Flavell, Transforming growth factor-β and the immune response: implications for anticancer therapy. Clinical cancer research, 2007. 13(18): p. 5262-5270.
Massagué, J., TGFβ in cancer. Cell, 2008. 134(2): p. 215-230.
Batlle, E. and J. Massagué, Transforming growth factor-β signaling in immunity and cancer. Immunity, 2019. 50(4): p. 924-940.
Derynck, R. and E.H. Budi, Specificity, versatility, and control of TGF-β family signaling. Science signaling, 2019. 12(570).
Kloss, C.C., et al., Dominant-negative TGF-β receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Molecular therapy, 2018. 26(7): p. 1855-1866.
Bollard, C.M., et al., Adapting a transforming growth factor β–related tumor protection strategy to enhance antitumor immunity. Blood, The Journal of the American Society of Hematology, 2002. 99(9): p. 3179-3187.
Narayan, V., et al., A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 2019. 37(7_suppl): p. TPS347-TPS347.
Ushiku, T., et al., Distinct expression pattern of claudin‐6, a primitive phenotypic tight junction molecule, in germ cell tumours and visceral carcinomas. Histopathology, 2012. 61(6): p. 1043-1056.
Reinhard, K., et al., An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science, 2020. 367(6476): p. 446-453.
Bera, T.K. and I. Pastan, Mesothelin is not required for normal mouse development or reproduction. Molecular and cellular biology, 2000. 20(8): p. 2902-2906.
Morello, A., M. Sadelain, and P.S. Adusumilli, Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer discovery, 2016. 6(2): p. 133-146.
Holtkamp, S., et al., Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood, 2006. 108(13): p. 4009-4017.
Zanoni, M., et al., 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained. Scientific reports, 2016. 6(1): p. 1-11.
Jinek, M., et al., A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. science, 2012. 337(6096): p. 816-821.
Doench, J.G., et al., Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nature biotechnology, 2016. 34(2): p. 184-191.
Thomas, D.A. and J. Massagué, TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer cell, 2005. 8(5): p. 369-380.
Tang, N., et al., TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI insight, 2020. 5(4).
Stüber, T., et al., Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer. Journal for immunotherapy of cancer, 2020. 8(1).
Foster, A.E., et al., Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-β receptor. Journal of immunotherapy (Hagerstown, Md.: 1997), 2008. 31(5): p. 500.
Nakamura, K., A. Kitani, and W. Strober, Cell contact–dependent immunosuppression by CD4+ CD25+ regulatory T cells is mediated by cell surface–bound transforming growth factor β. The Journal of experimental medicine, 2001. 194(5): p. 629-644.
Nakamura, K., et al., TGF-β1 plays an important role in the mechanism of CD4+ CD25+ regulatory T cell activity in both humans and mice. The Journal of Immunology, 2004. 172(2): p. 834-842.
Chen, M.-L., et al., Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proceedings of the National Academy of Sciences, 2005. 102(2): p. 419-424.
Fahlén, L., et al., T cells that cannot respond to TGF-β escape control by CD4+ CD25+ regulatory T cells. The Journal of experimental medicine, 2005. 201(5): p. 737-746.
Schmidt, A., et al., Comparative analysis of protocols to induce human CD4+ Foxp3+ regulatory T cells by combinations of IL-2, TGF-beta, retinoic acid, rapamycin and butyrate. PloS one, 2016. 11(2): p. e0148474.
Wright, G.P., et al., Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proceedings of the National Academy of Sciences, 2009. 106(45): p. 19078.
Thibault, B., et al., Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition. Cancer and Metastasis Reviews, 2014. 33(1): p. 17-39.
Teicher, B.A., Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer and Metastasis reviews, 2001. 20(1): p. 133-143.
Yu, Y., et al., Cancer-associated fibroblasts induce epithelial–mesenchymal transition of breast cancer cells through paracrine TGF-β signalling. British journal of cancer, 2014. 110(3): p. 724-732.
Dalal, B., P. Keown, and A. Greenberg, Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. The American journal of pathology, 1993. 143(2): p. 381.
Grady, W.M., et al., Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers. Cancer research, 1999. 59(2): p. 320-324.
Dunn, G.P., et al., Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol, 2002. 3(11): p. 991-8.
Galliher, A.J. and W.P. Schiemann, β 3 integrin and Src facilitate transforming growth factor-β mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast cancer research, 2006. 8(4): p. 1-16.
Chang, Z.L., et al., Rewiring T-cell responses to soluble factors with chimeric antigen receptors. Nature chemical biology, 2018. 14(3): p. 317.
Golumba-Nagy, V., et al., CD28-ζ CAR T cells resist TGF-β repression through IL-2 signaling, which can be mimicked by an engineered IL-7 autocrine loop. Molecular Therapy, 2018. 26(9): p. 2218-2230.
Hou, A.J., et al., TGF‐β–responsive CAR‐T cells promote anti‐tumor immune function. Bioengineering & translational medicine, 2018. 3(2): p. 75-86.
Liu, M., et al., TGF-β suppresses type 2 immunity to cancer. Nature, 2020. 587(7832): p. 115-120.
Li, S., et al., Cancer immunotherapy via targeted TGF-β signalling blockade in TH cells. Nature, 2020. 587(7832): p. 121-125.
Stadtmauer, E.A., et al., CRISPR-engineered T cells in patients with refractory cancer. Science, 2020. 367(6481): p. eaba7365.
Morgan, R.A., et al., Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Molecular Therapy, 2010. 18(4): p. 843-851.
Richman, S.A., et al., High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model. Cancer immunology research, 2018. 6(1): p. 36-46.
Lamers, C.H., et al., Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Molecular therapy, 2013. 21(4): p. 904-912.
Beatty, G.L., et al., Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies. Cancer immunology research, 2014. 2(2): p. 112-120.
Klebanoff, C.A., L. Gattinoni, and N.P. Restifo, Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? J Immunother, 2012. 35(9): p. 651-60.

FigS1.jpg
Supplemental Figure S1: Genomic TGFβ RII disruption in CAR T-cells specific for CLDN6 enhances their cytokine secretion TGFβ at any dose inhibits cytokine secretion of CLDN6-specific WT CAR 4-1BBζ T-cells. A: IL-2, B: IFNγ, C: TNFα, D: GM-CSF, E: Granzyme B, in the presence of antigen presenting iDCs as APCs. Of importance, amount of cytokines in TGFβRII KO CAR T-cells remain unimpaired and stable even at a very high dose of exogenous TGFβ. Cytokine secretion in either WT or KO groups proved to be antigen specific here as well. P values were determined by two-way Anova using multiple comparison test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Download PDF

Journal Publication

published 27 Nov, 2021

Read the published version in Journal of Translational Medicine →

Reviews received at journal
20 Aug, 2021
Reviewers invited by journal
20 Aug, 2021
Editor assigned by journal
20 Aug, 2021
First submitted to journal
17 Aug, 2021

You are reading this latest preprint version

CRISPR/Cas9-mediated TGFβRII Disruption Enhances Anti-tumor Efficacy of Human Chimeric Antigen Receptor T Cells in Vitro

Status:

Journal Publication

Version 1

Abstract

Figures

Background

Material And Methods

Results And Discussion

Discussion

Conclusion

Abbreviation

Declarations

References

Supplementary Files

Status:

Journal Publication

Version 1